title: Experimental Cannabinoid 2 Receptor Inhibition in CNS Injury-Induced Immunodeficiency Syndrome.
abstract: Severe CNS injury, such as stroke, traumatic brain injury, or spinal cord injury, is known to increase susceptibility to infections. The increased susceptibility to infection is due to an impaired immune response and is referred to as CIDS. The CB2 receptor on immune cells presents a potential therapeutic target in CIDS as activation of this receptor has been shown to be involved in immunosuppression. The main purpose of this study was to determine the impact of CB2 receptor inhibition on leukocyte activation within the microcirculation following endotoxin challenge in an experimental stroke model.
  
  
  
  Five experimental groups (male C57BL/6 mice, age: 6-8 weeks) were subjected to the following treatments: control; endotoxemia (LPS 5 mg/kg, i.v.); transient cerebral hypoxia-ischemia (HI) + endotoxemia; HI + endotoxemia + CB2 receptor antagonist (AM630 2.5 mg/kg, i.v.). HI was induced by unilateral carotid artery occlusion, followed by 50 minute exposure to a low oxygen atmosphere (8% O2 ). The CB2 receptor antagonist was given 15 min prior to LPS administration. Intravital microscopy (IVM) was carried out 2h after LPS administration. Brains were extracted and stained with tetrazolium chloride (TTC) to measure infarct volume.
  
  
  
  Compared to endotoxemic animals without CNS injury, mice subjected to HI displayed reduced leukocyte activation in intestinal submucosal venules indicative of CIDS. Administration of the CB2 receptor antagonist in animals with CIDS challenged with endotoxin restored peripheral leukocyte recruitment without a detrimental impact on infarct size.
  
  
  
  We conclude that the ECS is involved in the impaired immune response following CNS injury. Future studies should further explore the CB2 receptor pathway to develop novel therapies for CIDS.
authors.affiliation: Department of Anaesthesia, Dalhousie University, Halifax, Nova Scotia, Canada.|Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Ian
authors.initials: I
authors.lastname: Burkovskiy
authors.affiliation: Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.|Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Juan
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Anaesthesia, Dalhousie University, Halifax, Nova Scotia, Canada.|Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.|Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Christian
authors.initials: C
authors.lastname: Lehmann
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000209:etiology*; D000818:Animals; D002490:Central Nervous System / Q000276:immunology / Q000293:injuries*; D002493:Central Nervous System Diseases / Q000150:complications; D019446:Endotoxemia / Q000276:immunology; D007108:Immune Tolerance; D007962:Leukocytes / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008833:Microcirculation / Q000276:immunology; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors*; D020521:Stroke / Q000150:complications / Q000276:immunology
chemical_list: C571431:Cnr2 protein, mouse; D043885:Receptor, Cannabinoid, CB2
keywords: cannabinoids; immunodeficiency; microcirculation; stroke